Dicerna Pharma (DCRN) is scheduled to price tonight. The calendar is full of biotech companies but demand for this one is good due in no small part to the willingness of existing shareholders to buy a big part of the deal.
Dicerna is pre-clinical so sales are a long way off but the company does have a targeted drug delivery platform using RNAi which seems very promising. The first few slides of the Dicerna DCRN IPO Roadshow provide some pictures on how the two part process works.
Want the rest of the article?